Just another thought/link. If SI mentioned we have a partner for second COVID-ARDS trial, presumably NIH, wouldn't it mean the FDA have given the green light for potency assays, quality control etc. Maybe only awaiting formal minutes from FDA/OTAT before he can announce to market (but have in dialogue been given green light on consistency, potency measures etc). This makes me very bullish, along with timeframes mentioned, that there is an excellent chance Rem-L for aGvHD will be approved and marketed this year. Much needed for cash flow and to reverse the Share Price and attracting/committing the big investors. Wheels certainly seem in motion on a few fronts. Probably market volatility to continue before some big news drops - but doesn't seem too long off considering for the LT investors. All IMO.
Ann: MSB Presents at Edison Group Global Healthcare Conference, page-61
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |